The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCG

We aimed to investigate the genomic and tumor microenvironmental (TME) profiles in non-muscle invasive bladder cancer (NMIBC) and explore potential predictive markers for Bacillus Calmette–Guérin (BCG) treatment response in high-risk NMIBC patients (according to European Association of Urology (EAU)...

Full description

Saved in:
Bibliographic Details
Published inNPJ precision oncology Vol. 8; no. 1; pp. 216 - 13
Main Authors Xia, Qi-Dong, Sun, Jian-Xuan, Yao, Zhi-Peng, Lu, Jun-Lin, Liu, Chen-Qian, Xu, Jin-Zhou, An, Ye, Xu, Meng-Yao, Zhang, Si-Han, Zhong, Xing-Yu, Zeng, Na, Ma, Si-Yang, He, Hao-Dong, Hu, Heng-Long, Hu, Jia, Lu, Yi, Li, Bing, Chen, Yao-Bing, Liu, Zheng, Wang, Shao-Gang
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We aimed to investigate the genomic and tumor microenvironmental (TME) profiles in non-muscle invasive bladder cancer (NMIBC) and explore potential predictive markers for Bacillus Calmette–Guérin (BCG) treatment response in high-risk NMIBC patients (according to European Association of Urology (EAU) risk stratification). 40 patients with high-risk NMIBC (cTis-T1N0M0) who underwent en bloc resection followed by BCG instillation were retrospectively enrolled. Surgical samples were subjected to Next Generation Sequencing (NGS) and multiplex immunofluorescence (mIF) assay. Genomic profiling revealed high prevalences of alterations in TERT (55%), KDM6A (32.5%), FGFR3 (30%), PIK3CA (30%), TP53 (27.5%) and ARID1A (20%). TME analysis showed different proportions of macrophages, NK cells, T cells subsets in tumoral and stromal compartment. Multivariate analysis identified TERT C228T and alteration in KDM6A as two independent factors associated with inferior RFS. The study comprehensively depicted the genomic and TME profiles in NMIBC and identified potential predictive biomarkers for BCG treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-024-00725-4